Immune checkpoint inhibitor-associated aseptic meningitis: a pharmacovigilance study using the FDA adverse event reporting system (2011–2024)
ICIs-associated AM presents a clinically significant safety concern, particularly with ipilimumab-containing regimens. Rapid symptom onset underscores the need for vigilant neurological monitoring during early treatment phases. These findings warrant integration into clinical risk-assessment protocols and warrant further mechanistic investigation.
Authors
- Yunwei Pang (ORCID: https://orcid.org/0000-0002-7312-179X)
- Haixiong Wang (ORCID: https://orcid.org/0000-0001-9905-7899)
- Ze Wang (ORCID: https://orcid.org/0000-0002-8339-5567)
- Hui Guo (ORCID: https://orcid.org/0000-0001-9780-0845)
- Qian Guo (ORCID: https://orcid.org/0000-0003-2551-6882)
Institutions
- Shanxi Medical University (CN)
- Second Hospital of Shanxi Medical University (CN)
- Shanxi Cardiovascular Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-03
- DOI
- https://doi.org/10.3389/fimmu.2025.1654301
- Citations
- 1
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35